Haematologist Dr Cecily Forsyth and MPN AA advocate Nathalie Cook OAM have prepared an explanatory video for patients about the current Australian Pegasys supply. The video addresses the current and […]
The MPN AA has been advised of some very encouraging news about the Pegasys supply in Australia into the future. For details, please see the attached letter from the Australian […]
The MPNAA has just become aware of this extensive article about interferon, written by US haematologists and published in 2024 in Therapeutic Advances in Hematology. As so many more MPN […]
We are thrilled to advise that the Pharmaceutical Benefits Committee (PBAC) at its March meeting has recommended that ruxolitinib (jakavi) be listed on the Pharmaceutical Benefits Scheme (PBS) for adult […]
The MPN AA is delighted to advise that the Australian government has now approved the inclusion of momelotinib, now known as OMJJARA, onto the Pharmaceutical Benefits Scheme (PBS). Momelotinib was […]
The April 2025 edition of Haematologica features an excellent review series on MPNs. The authors of the introduction paper to the series, Australia’s Drs Steven Lane and Yin Yuan, explain […]
Early results from the Phase 3 clinical trial of the hepciden mimetic ‘rusfertide’ have recently been published. Rusfertide aims to overcome the need for phlebotomy in patients with polycythemia vera […]
The Therapeutic Goods Administration has updated its advice on a possible shortage of Pegasys in Australia. Its website now states that there is an anticipated shortage from June to September 2025. […]
The Medscape organisation in the US produces podcasts about Myelofibrosis. If you’d like to listen to the podcasts or even just read the transcripts, it’s simple to log in via […]
Haematologist Claire Harrison from Guys and St Thomas’ Hospital in the UK is one of the world’s leading MPN experts. In this podcast she provides an overview of some of […]
